Beyond Homologous Recombination: Functional Modules of Olaparib Resistance Revealed by CRISPR Screens
- 1Department of Biological and Biomedical Sciences, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan
Abstract
Clinical use of PARP inhibitors (PARPi), including olaparib, has improved outcomes for patients with BRCA1/2-mutant and homologous recombination (HR)-deficient tumors. However, acquired resistance remains a major limitation to their efficacy. CRISPR-Cas9 screening approaches have been developed to identify genetic drivers of PARPi resistance. However, differences in experimental conditions, library coverage, and selection design complicate comparisons across studies. In this review, we present a harmonized reanalysis of CRISPR knockout olaparib resistance screens to identify recurrent resistance-associated genes and pathways. Datasets with raw data were collected from the BioGRID ORCS database. Resistance hits identified in at least two screens were subjected to Reactome pathway-enrichment analysis and organized into functional modules. Using this approach, we identified eight modules: DNA-damage repair and replication stress; cell-cycle regulation; chromatin remodeling and histone modification; post-translational regulation; mitochondrial function; TGF-β and mTOR signaling; RNA processing and nucleocytoplasmic transport; and emerging adaptive mechanisms. Importantly, mitochondrial function genes were observed as recurrent hits, but their relation to olaparib resistance is underinvestigated. Our integrative analysis suggests that PARPi resistance is a complex, adaptive phenotype shaped by recurrent but context-dependent vulnerabilities across multiple cellular programs. This framework prioritizes candidate resistance drivers for validation and highlights directions for the design of combination therapies aimed at overcoming PARPi resistance.
Related
- Fingolimod overcomes cisplatin resistance in esophageal squamous cell carcinoma by targeting NUP54 to disrupt homologous recombination repair.
- Alternative Splicing of Homologous Recombination Genes Is Associated with Homologous Recombination Deficiency and Immunoregulatory Phenotypes in Breast Cancer
- Tobacco Carcinogen Induces Persistent DNA Damage and Homologous Recombination Dysregulation in Pancreatic Ductal Carcinogenesis
- Targeting G2/M checkpoint vulnerability in homologous recombination-proficient tumors: lessons from ovarian cancer models
- A non-allelic homologous recombination-induced inversion in intron 22 of the F8 gene is causative for haemophilia A in a Weimaraner male dog
BibTeX
@article{dildabayeva2026beyond,
title = {{Beyond Homologous Recombination: Functional Modules of Olaparib Resistance Revealed by CRISPR Screens}},
author = {Dana Dildabayeva and Diana Samarkhanova and Larissa Lezina},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209381},
url = {https://www.mdpi.com/1422-0067/27/20/9381},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Beyond Homologous Recombination: Functional Modules of Olaparib Resistance Revealed by CRISPR Screens
AU - Dana Dildabayeva
AU - Diana Samarkhanova
AU - Larissa Lezina
PY - 2026
DA - 2026/10/21
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209381
UR - https://www.mdpi.com/1422-0067/27/20/9381
AB - Clinical use of PARP inhibitors (PARPi), including olaparib, has improved outcomes for patients with BRCA1/2-mutant and homologous recombination (HR)-deficient tumors. However, acquired resistance remains a major limitation to their efficacy. CRISPR-Cas9 screening approaches have been developed to identify genetic drivers of PARPi resistance. However, differences in experimental conditions, library coverage, and selection design complicate comparisons across studies. In this review, we present a harmonized reanalysis of CRISPR knockout olaparib resistance screens to identify recurrent resistance-associated genes and pathways. Datasets with raw data were collected from the BioGRID ORCS database. Resistance hits identified in at least two screens were subjected to Reactome pathway-enrichment analysis and organized into functional modules. Using this approach, we identified eight modules: DNA-damage repair and replication stress; cell-cycle regulation; chromatin remodeling and histone modification; post-translational regulation; mitochondrial function; TGF-β and mTOR signaling; RNA processing and nucleocytoplasmic transport; and emerging adaptive mechanisms. Importantly, mitochondrial function genes were observed as recurrent hits, but their relation to olaparib resistance is underinvestigated. Our integrative analysis suggests that PARPi resistance is a complex, adaptive phenotype shaped by recurrent but context-dependent vulnerabilities across multiple cellular programs. This framework prioritizes candidate resistance drivers for validation and highlights directions for the design of combination therapies aimed at overcoming PARPi resistance.
SN - 1422-0067
ER -